Pea F.; Viale P., Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?, «CLINICAL PHARMACOKINETICS», 2008, 47, pp. 147 - 152 [articolo]
Pea, Federico, [Mutant Prevention Concentration: is it significant in the clinical practice?], «LE INFEZIONI IN MEDICINA», 2008, 16, pp. 12 - 23 [articolo]
Viale P; Pea F, General pharmacological considerations and dose adjustment in antibiotic therapy for HAP., in: Nosocomial penumonia: strategies for management., CHIRCHESTER, John Wiley & sons, 2007, pp. 173 - 190 [capitolo di libro]
Viale P.; Furlanut M.; Cristini F.; Cadeo B.; Pavan F.; Pea F., Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis, «DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE», 2007, 58, pp. 137 - 139 [articolo]
Kemal Agbaht Amalia Alcon Antonio Anzueto Elie Azoulay Emilio Bouza Almudena Burillo Jean Chastre Jose' M. Cisneros-HerrerosAlain Combes Sandra De Miranda George Dimopoulos Neus Fabregas Miguel Gallego Jose' Garnacho-Montero; VIALE, Pierluigi; PEA, Federico, Nosocomial Pneumonia: Strategies for Managment, in: Nosocomial Pneumonia Strategies for Management, GBR, John Wiley and Sons, Ltd, 2007, pp. 173 - 189 [commento giuridico]
Pea F.; Marioni G.; Pavan F.; Staffieri C.; Bottin R.; Staffieri A.; Furlanut M., Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose, «PHARMACOLOGICAL RESEARCH», 2007, 55, pp. 38 - 41 [articolo]
Pea F; Viale P, Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections., «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2007, 5, pp. 255 - 270 [articolo]
PEA F; VIALE P; PAVAN F; FURLANUT, Mario; PEA, Federico, Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy, «CLINICAL PHARMACOKINETICS», 2007, 46, pp. 997 - 1038 [articolo]
Viale P.; Pea F., What does it mean: Appropriate therapy for methicillin-resistant Staphylococcus aureus? [17], «CRITICAL CARE MEDICINE», 2007, 35, pp. 991 - 991 [replica/breve intervento]
Pea F.; Scudeller L.; Lugano M.; Baccarani U.; Pavan F.; Tavio M.; Furlanut M.; Della Rocca G.; Bresadola F.; Viale P., Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient [4], «CLINICAL INFECTIOUS DISEASES», 2006, 42, pp. 434 - 435 [replica/breve intervento]
Pea F.; Pavan F.; Lugatti E.; Dolcet F.; Talmassons G.; Screm M.C.; Furlanut M., Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis, «CLINICAL PHARMACOKINETICS», 2006, 45, pp. 287 - 295 [articolo]
Pea F.; Furlanut M.; Stellini R.; Bonardelli S.; Signorini L.; Pavan F.; Matheis A.; Portolani N.; Lorenzotti S.; Giulini S.M.; Viale P.; Carosi G., Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2006, 27, pp. 15 - 19 [articolo]
Pea F.; Viale P., The antimicrobial therapy puzzle: Could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?, «CLINICAL INFECTIOUS DISEASES», 2006, 42, pp. 1764 - 1771 [articolo]
Pea F.; Viale P.; Pavan F.; Tavio M.; Poz D.; Beltrame A.; Furlanut M., The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2006, 27, pp. 344 - 350 [articolo]
Pasticci M.B.; Altissimi M.; Azzara A.; Di Candilo F.; Lapalorcia L.M.; Giustelli G.; Pea F.; Baldelli F., Treatment of post-traumatic hand Staphylococcus aureus osteomyelitis with oral linezolid, «JOURNAL OF CHEMOTHERAPY», 2006, 18, pp. 425 - 429 [articolo]
